Status:
COMPLETED
Persistence of Immune Response After Vaccination With MCC
Lead Sponsor:
Novartis
Collaborating Sponsors:
Novartis Vaccines
Conditions:
Prevention of Meningococcal Infection
Eligibility:
All Genders
11-20 years
Phase:
PHASE4
Brief Summary
Persistence of Immune response after vaccination with MCC
Eligibility Criteria
Inclusion
- healthy adolescents vaccinated with Meningococcal C Conjugate vaccine
Exclusion
- ascertained or suspected disease caused by N. meningitidis
- household contact with individuals with proven N. meningitidis serogroup C infection
- significant acute or chronic infections
- any other serious disease
Key Trial Info
Start Date :
October 1 2004
Trial Type :
INTERVENTIONAL
End Date :
December 1 2005
Estimated Enrollment :
1244 Patients enrolled
Trial Details
Trial ID
NCT00310687
Start Date
October 1 2004
End Date
December 1 2005
Last Update
September 19 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital
Headington, Oxfordshire, United Kingdom, OX3 9DU